Recombinant Human CDCA3 Protein, N-His from ProteoGenix; catalogue ARO-P10694; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human CDCA3 Protein, also known as cell division cycle associated protein 3, is a protein that plays a crucial role in regulating cell division and proliferation. It is a member of the cell division cycle (CDC) family of proteins, which are involved in various stages of the cell cycle.
The structure of Recombinant Human CDCA3 Protein is composed of 325 amino acids, with a molecular weight of approximately 36 kDa. It contains an N-terminal domain and a C-terminal domain, which are connected by a linker region. The N-terminal domain is responsible for protein-protein interactions, while the C-terminal domain has a conserved motif that is crucial for its function.
Recombinant Human CDCA3 Protein is involved in the regulation of cell cycle progression, specifically in the G2/M phase transition. It has been shown to interact with several other proteins, including cyclin B1, Cdc2, and p53, which are all key players in cell cycle regulation.
One of the main functions of Recombinant Human CDCA3 Protein is to promote mitotic entry by activating the Cdc2-cyclin B1 complex. This complex is responsible for the initiation of mitosis, and Recombinant Human CDCA3 Protein has been shown to enhance its activity. Additionally, Recombinant Human CDCA3 Protein has been found to be essential for proper chromosome segregation during mitosis.
Recombinant Human CDCA3 Protein has a wide range of applications in both research and clinical settings. Its role in cell cycle regulation makes it a valuable tool for studying cell division and proliferation. It can be used in various in vitro and in vivo experiments to investigate its interaction with other proteins and its effects on cell cycle progression.
In addition, Recombinant Human CDCA3 Protein has potential clinical applications. It has been found to be overexpressed in several types of cancer, including lung, breast, and colon cancer. This makes it a potential diagnostic marker for these types of cancer, as well as a potential target for cancer therapy.
Furthermore, Recombinant Human CDCA3 Protein has been shown to play a role in drug resistance in cancer cells. It has been found to interact with proteins involved in drug metabolism and transport, suggesting that it may be involved in the development of drug resistance. This highlights its potential as a therapeutic target for overcoming drug resistance in cancer treatment.
In conclusion, Recombinant Human CDCA3 Protein is a crucial protein involved in cell cycle regulation and has a diverse range of functions. Its structure, with an N-terminal domain responsible for protein-protein interactions and a C-terminal domain crucial for its function, allows it to interact with other proteins and play a role in cell cycle progression. Its potential applications in research and clinical settings make it a valuable tool for understanding cell division and proliferation, as well as a potential diagnostic marker and therapeutic target for cancer.
ProteoGenix catalogue number ARO-P10694. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 18.91 kDa; Fragment: Ser119-Ser268; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
